Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03694249 · ClinicalTrials.gov registry record · Phase 2
Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence
A Phase 2 study of Malignant Solid Tumor, sponsored by Vanderbilt-Ingram Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT03694249: Active Phase 2 study of Malignant Solid Tumor, sponsored by Vanderbilt-Ingram Cancer Center.
NCT03694249 is a Phase 2 study of Malignant Solid Tumor that is active but no longer recruiting, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 30 participants, below the 164-participant average among 8 other Malignant Solid Tumor trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03694249, a Phase 2 study of Malignant Solid Tumor, is active but no longer recruiting, sponsored by Vanderbilt-Ingram Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Ifetroban Sodium
Study Locations (1)
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2026-04 |
| Phase | Phase 2 |
What the registry record for NCT03694249 still lists
NCT03694249 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 164-participant average among 8 other Malignant Solid Tumor trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Malignant Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03694249 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT03694249 about?
NCT03694249 is a clinical study titled "Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence". This pilot trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment and spreading throughout the body. Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on the...
What is the current status of trial NCT03694249?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2018-12-12. Estimated completion is 2026-04.
What conditions does trial NCT03694249 study?
This clinical trial studies the following conditions: Malignant Solid Tumor.
What interventions are being tested in trial NCT03694249?
The interventions under investigation include: Placebo (OTHER), Ifetroban Sodium (DRUG).
Who is sponsoring clinical trial NCT03694249?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03694249 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03694249's enrollment target sits among peer trials
30 8th of 8 higher than 1 of 8 other Malignant Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors
COMPLETED · Phase 2
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Pragmatic Research of Acupuncture and Counseling eXtended to Inpatient Services
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI